Comparison
2p25 3 Microduplication Syndrome C6012304 vs 11p15 4 Microduplication Syndrome C4749508
Clinical comparison between 2p25 3 Microduplication Syndrome and 11p15 4 Microduplication Syndrome for differential diagnosis and treatment planning.
2p25 3 Microduplication Syndrome C6012304
A rare chromosomal condition involving extra genetic material on chromosome 2. Features vary widely based on the genes involved. Treatment focuses on managing specific symptoms.
11p15 4 Microduplication Syndrome C4749508
A rare genetic disorder involving duplication of material on chromosome 11, leading to varied developmental features. Requires individualized medical assessment.
6 comparison axes
Onset
2p25 3 Microduplication Syndrome C6012304
0-5
11p15 4 Microduplication Syndrome C4749508
0-null
Onset patterns differ
Severity
2p25 3 Microduplication Syndrome C6012304
severe
11p15 4 Microduplication Syndrome C4749508
moderate
Different severity levels
Chronic
2p25 3 Microduplication Syndrome C6012304
Chronic
11p15 4 Microduplication Syndrome C4749508
Chronic
Differing course
Communicable
2p25 3 Microduplication Syndrome C6012304
No
11p15 4 Microduplication Syndrome C4749508
No
Different transmission
Body System
2p25 3 Microduplication Syndrome C6012304
congenital
11p15 4 Microduplication Syndrome C4749508
congenital
Same/different system
Category
2p25 3 Microduplication Syndrome C6012304
rare-disease
11p15 4 Microduplication Syndrome C4749508
genetic
Different category
Bottom line
2p25-3-microduplication-syndrome-C6012304 and 11p15-4-microduplication-syndrome-C4749508 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 2p25 3 Microduplication Syndrome C6012304 | 11p15 4 Microduplication Syndrome C4749508 | Discriminating power |
|---|---|---|---|
| Developmental features | Variable features linked to extra 2p25.3 material; specific signs are not established in the source. | Varied developmental features linked to 11p15.4 duplication; details are not established here. | Low |
| Age at recognition | Source onset range is 0–5 years. | Onset is listed as 0 with an unspecified upper limit, so timing is uncertain. | Moderate |
| Overall clinical burden | Classified as severe, though individual expression may vary. | Classified as moderate, with individualized assessment required. | Moderate |
When to favor each condition
Choose 2p25 3 Microduplication Syndrome C6012304 when
A confirmed extra segment at 2p25.3
The chromosomal location, not severity alone, identifies this condition.
High
Symptoms recognized from birth through early childhood
The supplied onset range is 0–5 years, but confirmation still requires genetics.
Moderate
A severe congenital presentation needing symptom-focused care
Severity is listed as severe; management is individualized and not diagnosis-specific here.
Low
Choose 11p15 4 Microduplication Syndrome C4749508 when
A confirmed duplication at 11p15.4
The chromosome 11 locus distinguishes it from a chromosome 2 duplication.
High
Developmental concerns with moderate reported severity
Moderate severity supports consideration, but does not establish the diagnosis.
Moderate
Onset timing is unclear
The source does not define a complete onset range for this condition.
Low
How key tests differ
| Test | 2p25 3 Microduplication Syndrome C6012304 | 11p15 4 Microduplication Syndrome C4749508 | Interpretation |
|---|---|---|---|
| Chromosomal microarray | May detect extra material involving 2p25.3. | May detect duplication involving 11p15.4. | The genomic location distinguishes the findings; clinical correlation is required. |
| Karyotype or targeted cytogenetic study | May support a chromosome 2 imbalance if large enough to detect. | May support a chromosome 11 imbalance if detectable by the method. | A normal result does not exclude a smaller duplication; specialist interpretation is needed. |
| Clinical developmental assessment | Documents variable features but cannot localize the duplication. | Documents varied developmental features without identifying the locus. | Assessment guides care but does not replace genetic confirmation. |
Prognosis comparison
2p25 3 Microduplication Syndrome C6012304
- Outcome
- Long-term outcome is not established; severity is listed as severe and course as chronic.
- Factors
- Genes involved, confirmed duplication size, and individual clinical findings may influence outlook.
11p15 4 Microduplication Syndrome C4749508
- Outcome
- Long-term outcome is not established; severity is listed as moderate and course as chronic.
- Factors
- Duplication extent, developmental findings, and individualized assessment may influence outlook.
Time frame: From early life into ongoing follow-up; no specific survival interval is established.
Precise genomic result and evolving clinical needs matter more than the category label.
Complications comparison
| Complication | Presentation |
|---|---|
| Developmental complexity | May be substantial because severity is listed as severe, but complications are unspecified. May occur with moderate severity; specific complications are not established. Do not infer particular organ complications from these sparse descriptions. |
| Need for ongoing care | Chronic course with symptom-focused management. Chronic course requiring individualized assessment. Both may need long-term multidisciplinary follow-up. |
| Diagnostic uncertainty | Wide variation by involved genes limits prediction. Varied developmental features likewise limit prediction. Family-specific genetic results should guide counseling. |
Patient education highlights
- HighGenetic confirmation
The diagnosis depends on identifying the duplicated chromosomal region, not on symptoms alone.
- HighVariable presentation
Features can differ widely; this comparison does not predict an individual child’s findings.
- MediumCare planning
Neither condition is communicable. Care focuses on identified needs and clinician-directed follow-up.